At Baxter, we believe every person deserves a chance for a healthy life, free from illness and full of possibility. We focus each day on delivering transformative innovations that bring smarter, more personalized care to all of us.
Our Commitment to Providers and Patients
We work at the critical intersection where innovations that save and sustain lives meet the physicians, nurses and pharmacists who make it happen. We are committed to improving outcomes for patients, and helping our partners meet the evolving challenges and opportunities in healthcare around the world. Learn more about our diverse specialties.
Baxter is focused on providing renal patients (Chronic and acute) the best possible life by elevating the standards of care across all therapeutic options, whether that be in-center or home care or ICU. Baxter is committed to addressing the individual needs of patients by supporting greater access to innovative renal care products, therapies, services and support globally.
At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
The Novartis Mission and Vision
Our mission is to discover new ways to improve and extend people`s lives.
Our vision is to be a trusted leader in changing the practice of medicine.
Novartis is structured to deliver innovative products, exploit global scale, and respond to new opportunities and risks. Our businesses - Innovative Medicines, Alcon and Sandoz - are supported by functional organizations with global scale. Research and development (R&D) is at the core of our company and central to the Novartis strategy.
Fortune's Most Admired Pharmaceutical Companies 2018
Novartis has been ranked #3 by Fortune magazine as one of the most admired pharmaceutical companies in the world — our 14th consecutive year in the top three.
Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) is a Saudi Joint–Stock company with a fully paid-up capital of SR 1,200,000,000 . It was established in 1986 . SPIMACO Addwaeih’s core business is medical and pharmaceutical, which includes development, manufacturing and sales of pharmaceutical products and medical appliances. Moreover, SPIMACO also has ownership in number of joint stock ans limited liabilities companies inside and outside the Kingdom . SPIMACO has developed a strong position in Saudi Arabia and is well positioned to sustain its growth and have a sound platform to serve export markets.
SPIMACO main manufacturing facility – Al–Qassim Pharmaceutical Plant was planned , constructed and equipped up to the highest quality levels. SPIMACO earned a lot of national quality awards and attained major international certifications.
SPIMACO serves successfully several markets locally and internationally and have built superior relations with regulatory bodies and the medical professions at large. The heavy investments in regulatory, marketing, sales and international alliances gave SPIMACO the market capabilities to prosper and overtake a lot of competitors.
An important and distinctive advantage of SPIMACO strategy is its relations with multinational companies. A very flexible, objective and versatile approach let to a multitude of relationships that served the interests of all parties. SPIMACO is a successful joint stock company and it has one of the most actively traded shares in the Saudi stock market.
AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Zemplar is the first selective Vit-D receptor activator that, it affords effective management of SHPT in patients with all stages of CKD ZEMPLAR has been shown to reduce PTH with less impact on P and Ca when compared to calcitriol. ZEMPLAR provides superior reduction of iPTH to target levels with minimal effects on calcium with HD patients compared with Cinacalcet plus low-dose vitamin D therapy
Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company. LEO Pharma develops, manufactures and markets pharmaceutical drugs in more than 100 countries globally. The company has its own sales forces in 61 countries and employs around 4,800 people worldwide. LEO Pharma is headquartered in Denmark and is wholly owned by the LEO Foundation.
At LEO Pharma, we are dedicated to developing drugs and therapies that deliver unique value to patients and societies all around the world. Adapting quickly to new demands, we supply medicines and solutions to patients suffering from skin infections and diseases such as psoriasis, acne and eczema, as well as conditions that require supportive treatments such as thrombosis, kidney disease and cancer.